Active Recruiting Current Clinical Trials with CSF-1R Inhibitors in Various Malignancies

NCI IdentifierStudy DescriptionTumor TypeDrug Combination with CSF-1R inhibitor*Phase
NCT02777710Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersAdvanced Cancers, Colorectal, Pancreatic CancerDurvalumabPexidartinib(PLX-3397)*I
NCT02401815PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid TumorsGastrointestinal Stromal TumorsPLX-3397*PLX9486SunitinibI/II
NCT02071940PLX3397 KIT in Acral and mucosal MelanomaMelanomaPLX-3397*II
NCT02584647PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsSarcoma, Malignant Peripheral Nerve Sheath TumorsSirolimusPLX-3397*I/II
NCT03069469Study of DCC-3014 in Patients With Advanced MalignanciesAdvanced MalignantDCC-3014*I
NCT02880371A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid TumorsAdvanced Solid Tumors, Platinum Resistant ovarian cancer, pancreatic ductal adenocarcinomaARRY-382*PembrolizumabI/II
NCT02829723Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid TumorsAdvanced Solid TumorsBLZ945*PDR001I/II

*There are also clinical trials evaluating monoclonal Antibodies Targeting CSF-1R, including NCT02718911, NCT03238027, NCT02471716, NCT03101254, NCT03336216, NCT03431948, and NCT03335540, which are assessing LY3022855, SNDX-6352, FPA008 (Cabiralizumab), LY3022855, FPA008, FPA008 and FPA008, respectively